Lead Product(s) : Melphalan
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Xi'an Guokang Ruijin Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Casi Pharmaceuticals Announces Renewal Of Exclusive Distribution Agreement For Evomela® In China
Details : Under the terms of the agreement, China Resources Pharmaceutical Commercial Group International Trading Co., will continue to be the sole distributor for the sale of EVOMELA® (melphalan) for Injection in China.
Product Name : Evomela
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
April 03, 2022
Lead Product(s) : Melphalan
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Xi'an Guokang Ruijin Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Daratumumab,Bortezomib,Melphalan
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DARZALEX® SC reduces administration time from hours to minutes and demonstrates consistent efficacy with a reduction in administration-related reactions compared to intravenous DARZALEX® (daratumumab).
Product Name : Darzalex Faspro
Product Type : Antibody
Upfront Cash : Inapplicable
April 08, 2020
Lead Product(s) : Daratumumab,Bortezomib,Melphalan
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Delcath Systems Prices $22M Public Offering
Details : Delcath intends to use the net proceeds of the offering for working capital and general corporate purposes including the continued development of Melphalan/HDS.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
January 05, 2020
Reset All
